ClinicalTrials.gg
CompletedNCT06837155Updated Jun 6, 2025

A QT/QTc Evaluation Study of TS-172 in Healthy Adult Subjects

A Phase 1 interventional study of TS-172 20 mg and TS-172 90 mg in Healthy Volunteers, sponsored by Taisho Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 18 Years to 39 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-06.

Sponsored by Taisho Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 39 Years
Sex
All
01

Study summary

A clinical study to evaluate the effects on QT/QTc interval of TS-172 in healthy adults subjects

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Taisho Pharmaceutical Co., Ltd. is the lead sponsor of 43 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 39 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Japanese healthy subjects aged =>18 and \<40 years at the time of obtaining
  2. Subjects whose body weight is >=40 kg at the screening test, and is >=18.5 and \<25.0
  3. Subjects with both heart rates are =>45 and =\<100 beats/min on a standard 12-lead at the screening test and before drug administration in Period 1

Exclusion criteria

Exclusion criteria

  1. Subjects with a history of to moxifloxacin or other quinolone antibiotics
  2. Subjects with a family history or risk factors for aortic aneurysm or aortic dissection (e.g., Marfan syndrome)
  3. Subjects with a family history of sudden death
  4. Subjects with congenital diseases, heart diseases, or medical history of such conditions
  5. Subjects with risk factors for Torsades de Pointes (TdP) (e.g., heart failure, hypokalemia, or a family history of long syndrome) or medical history of such conditions
  6. Subjects with medical history of syncope suspected to be related to TdP, unexplained syncope, or seizures
  7. Subjects with standard 12-lead waveforms that make it difficult to evaluate QTc prolongation (e.g., drift, EMG interference, T wave morphology, significant sinus arrhythmia, or frequent ectopic beats) at the screening and before the administration of the study drug in Period 1
  8. Subjects with a QTcF (QT interval corrected using Fridericia's formula) of =>450 msec in the standard 12-lead ECG test at the screening and before the administration of the study drug in Period 1
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    TS-172 20 mg

    Drug: TS-172 20 mg

  • Experimental
    TS-172 90 mg

    Drug: TS-172 90 mg

  • Active comparator
    Moxifloxacin

    Drug: Moxifloxacin

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • oral administration of TS-172 20 mg

  • oral administration of TS-172 90 mg

  • oral administration of moxifloxacin 400 mg

  • DrugPlacebo

    oral administration of placebo

06

What researchers measure

Primary outcomes

  1. QTcF:QT-interval corrected by Fridericia corrections in Holter ECGs

    Time frame: Up to 24 hours postdose during each period

07

Study locations

1 site
  • Taisho Pharmaceutical Co., Ltd selected site
    Tokyo, Japan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2025 to primary completion in May 2025, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2025
First posted
Feb 20, 2025
StartActual
Mar 3, 2025
Primary completionActual
May 20, 2025
CompletionActual
May 26, 2025
Last update
Jun 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06837155
Responsible party
Sponsor
First posted
Feb 20, 2025
Start date
Mar 3, 2025
Primary completion
May 20, 2025
Completion
May 26, 2025
Last update
Jun 6, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TS-172

Start the discussion